Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.
2.

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.

Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV.

Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019. Review.

3.

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.

Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, Linker RA, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wildemann B, Haas J, Klotz L, Wiendl H, Ruck T, Meuth SG.

J Neurol. 2019 Jan;266(1):165-173. doi: 10.1007/s00415-018-9117-z. Epub 2018 Nov 16.

PMID:
30446966
4.

Systematic evaluation of stroke thrombectomy in clinical practice: The German Stroke Registry Endovascular Treatment.

Alegiani AC, Dorn F, Herzberg M, Wollenweber FA, Kellert L, Siebert E, Nolte CH, von Rennenberg R, Hattingen E, Petzold GC, Bode FJ, Pfeilschifter W, Schäfer JH, Wagner M, Röther J, Eckert B, Kraft P, Pham M, Boeckh-Behrens T, Wunderlich S, Bernkopf K, Reich A, Wiesmann M, Mpotsaris A, Psychogios M, Liman J, Maier I, Berrouschot J, Bormann A, Limmroth V, Spreer J, Petersen M, Krause L, Lowens S, Kraemer C, Zweynert S, Lange KS, Thonke S, Kastrup A, Papanagiotou P, Alber B, Braun M, Fiehler J, Gerloff C, Dichgans M, Thomalla G.

Int J Stroke. 2019 Jun;14(4):372-380. doi: 10.1177/1747493018806199. Epub 2018 Oct 22. Erratum in: Int J Stroke. 2018 Dec 17;:1747493018816194.

PMID:
30346260
5.

The BETACONNECT™ system: MS therapy goes digital.

Limmroth V, Bartzokis I, Bonmann E, Kusel P, Schreiner T, Schürks M.

Neurodegener Dis Manag. 2018 Dec;8(6):399-410. doi: 10.2217/nmt-2018-0030. Epub 2018 Oct 3. Review.

6.

Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.

Huhn K, Bayas A, Doerck S, Frank B, Gerbershagen K, Hellwig K, Kallmann B, Kleinschnitz C, Kleiter I, Lee DH, Limmroth V, Mäurer M, Meuth S, Rieckmann P, Ruck T, Gold R, Linker RA.

J Neurol. 2018 Jul;265(7):1521-1527. doi: 10.1007/s00415-018-8871-2. Epub 2018 Apr 25.

PMID:
29696498
7.

Letter to the editor to the paper: "Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis".

Ziemssen T, Limmroth V.

Mult Scler Relat Disord. 2018 May;22:57-58. doi: 10.1016/j.msard.2018.03.013. Epub 2018 Mar 19. No abstract available.

PMID:
29574354
8.

Autoinjector preference among patients with multiple sclerosis: results from a national survey.

Limmroth V, Reischl J, Mann B, Morosov X, Kokoschka A, Weller I, Schreiner T.

Patient Prefer Adherence. 2017 Aug 3;11:1325-1334. doi: 10.2147/PPA.S137741. eCollection 2017.

9.

Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.

Limmroth V, Ziemssen T, Lang M, Richter S, Wagner B, Haas J, Schmidt S, Gerbershagen K, Lassek C, Klotz L, Hoffmann O, Albert C, Schuh K, Baier-Ebert M, Wendt G, Schieb H, Hoyer S, Dechend R, Haverkamp W.

BMC Neurol. 2017 Jan 18;17(1):11. doi: 10.1186/s12883-016-0789-7.

10.

Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).

Meissner A, Limmroth V.

Mult Scler Relat Disord. 2016 Jul;8:19-26. doi: 10.1016/j.msard.2016.04.002. Epub 2016 Apr 21. Review.

PMID:
27456870
11.

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.

BMC Neurol. 2016 Jul 12;16:98. doi: 10.1186/s12883-016-0625-0.

12.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678. eCollection 2016 Jun.

13.

Comment: Monoclonal antibodies in chronic migraine-Are early effects meaningful?

Limmroth V.

Neurology. 2016 Jul 5;87(1):47. doi: 10.1212/WNL.0000000000002819. Epub 2016 Jun 8. No abstract available.

PMID:
27281535
14.

[Could salt trigger autoimmune diseases?].

Limmroth V.

MMW Fortschr Med. 2016 May 12;158(9):38. doi: 10.1007/s15006-016-8203-3. German. No abstract available.

PMID:
27155703
15.

Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.

Zettl UK, Bauer-Steinhusen U, Glaser T, Czekalla J, Hechenbichler K, Limmroth V, Hecker M.

Adv Ther. 2016 May;33(5):834-47. doi: 10.1007/s12325-016-0325-6. Epub 2016 Apr 18.

PMID:
27090116
16.

[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H.

Nervenarzt. 2016 Jun;87(6):645-59. doi: 10.1007/s00115-016-0077-1. Review. German.

PMID:
26927677
17.

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.

Dankowski T, Buck D, Andlauer TF, Antony G, Bayas A, Bechmann L, Berthele A, Bettecken T, Chan A, Franke A, Gold R, Graetz C, Haas J, Hecker M, Herms S, Infante-Duarte C, Jöckel KH, Kieseier BC, Knier B, Knop M, Kümpfel T, Lichtner P, Lieb W, Lill CM, Limmroth V, Linker RA, Loleit V, Meuth SG, Moebus S, Müller-Myhsok B, Nischwitz S, Nöthen MM, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Strauch K, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Waldenberger M, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Hemmer B, Ziegler A; German Competence Network for Multiple Sclerosis (KKNMS).

Genet Epidemiol. 2015 Dec;39(8):601-8. doi: 10.1002/gepi.21933. Epub 2015 Oct 26.

PMID:
26497834
18.

Case Report: Human Bocavirus Associated Pneumonia as Cause of Acute Injury, Cologne, Germany.

Krakau M, Gerbershagen K, Frost U, Hinzke M, Brockmann M, Schildgen V, Gomann A, Limmroth V, Dormann A, Schildgen O.

Medicine (Baltimore). 2015 Oct;94(42):e1587. doi: 10.1097/MD.0000000000001587.

19.

Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program.

Katsarava Z, Ehlken B, Limmroth V, Taipale K, Patel SN, Niemczyk G, Rehberg-Weber K, Wernsdörfer C; C.A.R.E. Study Group.

BMC Neurol. 2015 Sep 22;15:170. doi: 10.1186/s12883-015-0426-x.

20.

[Current aspects of therapy conversion for multiple sclerosis].

Kolber P, Luessi F, Meuth SG, Klotz L, Korn T, Trebst C, Tackenberg B, Kieseier B, Kümpfel T, Fleischer V, Tumani H, Wildemann B, Lang M, Flachenecker P, Meier U, Brück W, Limmroth V, Haghikia A, Hartung HP, Stangel M, Hohlfeld R, Hemmer B, Gold R, Wiendl H, Zipp F.

Nervenarzt. 2015 Oct;86(10):1236-47. doi: 10.1007/s00115-015-4368-8. Review. German.

PMID:
26269289
21.

A systematic review of aspirin in primary prevention: is it time for a new approach?

Brotons C, Benamouzig R, Filipiak KJ, Limmroth V, Borghi C.

Am J Cardiovasc Drugs. 2015 Apr;15(2):113-33. doi: 10.1007/s40256-014-0100-5. Review.

22.

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.

Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kümpfel T, Hohlfeld R, Mäurer M, Stangel M, Straeten V, Limmroth V, Weber T, Kleinschnitz C, Wattjes MP, Svenningsson A, Olsson T, Hartung HP, Hermsen D, Tumani H, Adams O, Kieseier BC.

Mult Scler. 2015 Jul;21(8):1036-44. doi: 10.1177/1352458514556296. Epub 2014 Nov 12.

PMID:
25392339
23.

[Juvenile multiple sclerosis is increasing].

Limmroth V.

MMW Fortschr Med. 2014 Jun 26;156(12):26. German. No abstract available.

PMID:
25369676
24.

Treatment of relapsing-remitting multiple sclerosis: current and future algorithms.

Limmroth V.

Eur Neurol. 2014;72 Suppl 1:35-8. doi: 10.1159/000367624. Epub 2014 Sep 26. No abstract available.

25.

[The transient ischemic attack (TIA)--a valid instrument for intern process analyses in neurological departments].

Bayerer B, Frost U, Claus C, Schmidt Ch, Limmroth V.

Versicherungsmedizin. 2014 Sep 1;66(3):137-41. German.

PMID:
25272659
26.

Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a.

Limmroth V, Gerbershagen K.

Expert Opin Drug Deliv. 2014 Dec;11(12):1969-78. doi: 10.1517/17425247.2014.943181. Epub 2014 Sep 26.

PMID:
25255732
27.

CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.

Limmroth V, Barkhof F, Desem N, Diamond MP, Tachas G; ATL1102 Study Group.

Neurology. 2014 Nov 11;83(20):1780-8. doi: 10.1212/WNL.0000000000000926. Epub 2014 Sep 19. Erratum in: Neurology. 2015 Jan 6;84(1):105.

28.

[Writer's cramp amd Raynaud phenomenon. How do they go together?].

Limmroth V.

MMW Fortschr Med. 2014 Jun 12;156(11):32. German. No abstract available.

PMID:
25022088
29.

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kümpfel T, Mäurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, Hermsen D, Kleinschnitz C, Hartung HP, Wattjes MP, Svenningson A, Major E, Olsson T, Kieseier BC, Adams O.

Ann Neurol. 2014 Dec;76(6):792-801. doi: 10.1002/ana.24153. Epub 2014 May 8.

30.

Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study.

Doerner M, Beckmann K, Knappertz V, Kappos L, Hartung HP, Filippi M, O'Connor PW, Arnason B, Cook S, Jeffery D, Comi G, Limmroth V.

Eur Neurol. 2014;71(3-4):173-9. doi: 10.1159/000355530. Epub 2014 Jan 21.

PMID:
24457374
31.

Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.

Zettl UK, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Limmroth V; Study Group.

BMC Neurol. 2013 Sep 6;13:117. doi: 10.1186/1471-2377-13-117.

32.

Multiple sclerosis: oral BG12 for treatment of relapsing-remitting MS.

Limmroth V.

Nat Rev Neurol. 2013 Jan;9(1):8-10. doi: 10.1038/nrneurol.2012.231. Epub 2012 Nov 13. No abstract available.

PMID:
23147843
33.

Anti-JC-virus antibody prevalence in a German MS cohort.

Warnke C, Dehmel T, Posevitz-Fejfár A, Chan A, Berthele A, Schmidt S, Haas J, Kronsbein HC, Seitz F, Tackenberg B, Mäurer M, Gerbershagen K, Limmroth V, Adams O, Hartung HP, Gold R, Hemmer B, Wiendl H, Kieseier BC.

Mult Scler. 2012 Jul;18(7):1054-5. doi: 10.1177/1352458511429955. No abstract available.

PMID:
22740609
34.

[Generation 55+: leadership and motivation of generations in hospitals].

Schmidt CE, Möller J, Schmidt K, Gerbershagen MU, Wappler F, Limmroth V, Padosch SA, Bauer M.

Anaesthesist. 2012 Jul;61(7):630-4, 636-9. doi: 10.1007/s00101-012-2055-8. German.

PMID:
22740193
35.

Oral triptans in the preventive management of cluster headache.

Pageler L, Limmroth V.

Curr Pain Headache Rep. 2012 Apr;16(2):180-4. doi: 10.1007/s11916-012-0251-5. Review.

PMID:
22382758
37.

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.

Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, Dawson K, O'Neill GN.

Mult Scler. 2012 Mar;18(3):314-21. doi: 10.1177/1352458511421054. Epub 2011 Aug 30.

PMID:
21878455
38.

Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.

Lampl C, You X, Limmroth V.

Eur J Neurol. 2012 Jan;19(1):142-8. doi: 10.1111/j.1468-1331.2011.03460.x. Epub 2011 Jul 1.

PMID:
21718390
39.

[Generation Y : recruitment, retention and development].

Schmidt CE, Möller J, Schmidt K, Gerbershagen MU, Wappler F, Limmroth V, Padosch SA, Bauer M.

Anaesthesist. 2011 Jun;60(6):517-24. doi: 10.1007/s00101-011-1886-z. German.

PMID:
21437753
40.

Frovatriptan for prophylactic treatment of cluster headache: lessons for future trial design.

Pageler L, Katsarava Z, Lampl C, Straube A, Evers S, Diener HC, Limmroth V.

Headache. 2011 Jan;51(1):129-34. doi: 10.1111/j.1526-4610.2010.01772.x. Epub 2010 Oct 1.

PMID:
21198573
41.

BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis.

MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, O'Neill GN, Dawson K.

J Neurol. 2011 Mar;258(3):449-56. doi: 10.1007/s00415-010-5777-z. Epub 2010 Oct 21.

PMID:
20963434
42.

Headache attributed to a substance or its withdrawal.

Diener HC, Katsarava Z, Limmroth V.

Handb Clin Neurol. 2010;97:589-99. doi: 10.1016/S0072-9752(10)97051-6.

PMID:
20816457
43.

Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells.

Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E.

Eur Neurol. 2010;63(5):311-7. doi: 10.1159/000302687. Epub 2010 May 5.

PMID:
20453514
44.

Single nucleotide polymorphisms of the serotonin transporter gene in migraine--an association study.

Bayerer B, Engelbergs J, Savidou I, Boes T, Küper M, Schorn CF, Wissmann A, Knop D, Diener HC, Limmroth V.

Headache. 2010 Feb;50(2):319-22. doi: 10.1111/j.1526-4610.2009.01553.x. Epub 2009 Oct 21.

PMID:
19845785
45.

Fatigue is not associated with impaired function of regulatory T cells in untreated patients with multiple sclerosis.

Yaldizli O, Kumar M, Vago S, Kreuzfelder E, Limmroth V, Putzki N.

Eur Neurol. 2009;62(6):321-6. doi: 10.1159/000236375. Epub 2009 Sep 10.

PMID:
19752558
46.

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V.

Eur J Neurol. 2010 Jan;17(1):31-7. doi: 10.1111/j.1468-1331.2009.02728.x. Epub 2009 Jul 9.

PMID:
19614963
47.

Erythropoietin overrides the triggering effect of DNA platination products in a mouse model of cisplatin-induced neuropathy.

Yoon MS, Katsarava Z, Obermann M, Schäfers M, Liedert B, Dzagnidze A, Kribben A, Egensperger R, Limmroth V, Diener HC, Thomale J.

BMC Neurosci. 2009 Jul 15;10:77. doi: 10.1186/1471-2202-10-77.

48.

Pain prevalence and risk distribution among inpatients in a German teaching hospital.

Gerbershagen K, Gerbershagen HJ, Lutz J, Cooper-Mahkorn D, Wappler F, Limmroth V, Gerbershagen M.

Clin J Pain. 2009 Jun;25(5):431-7. doi: 10.1097/AJP.0b013e31819ff515.

PMID:
19454878
49.

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.

Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V.

Eur J Neurol. 2009 Mar;16(3):424-6. doi: 10.1111/j.1468-1331.2008.02519.x.

PMID:
19187261
50.

Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis.

Putzki N, Pfriem A, Limmroth V, Yaldizli O, Tettenborn B, Diener HC, Katsarava Z.

Eur J Neurol. 2009 Feb;16(2):262-7. doi: 10.1111/j.1468-1331.2008.02406.x. Epub 2008 Dec 9.

PMID:
19138330

Supplemental Content

Loading ...
Support Center